ALK and non-small cell lung carcinoma: The results of the phase III KEYNOTE 189 study showed that pembrolizumab combined with chemotherapy had extended the overall survival time from 10.6 months to 22 months for patients with EGFR/ALK‐negative advanced nonsquamous NSCLC patients.6